0QW0 Stock Price, Chart, Stats & News

argenx SE is a biotechnology firm dedicated to advancing innovative treatments for autoimmune conditions across key global markets, including the United States, several European nations (the Netherlands, Belgium, Switzerland, Germany, France), and Japan. The company's flagship experimental drug, efgartigimod, is currently in advanced Phase III clinical trials for conditions such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Additionally, efgartigimod is being investigated in Phase II/III studies for bullous pemphigoid and idiopathic inflammatory myopathy, with a preclinical formulation, ENHANZE SC, also under development.